

**REMARKS**

Applicant respectfully requests reconsideration. Claims 1-18 were previously pending in this application. By this amendment, Applicant is amending claim 7. No new claims have been added. As a result, claims 1-18 are pending for further examination with claim 1 being the independent claim. No new matter has been added.

Applicant also is amending the specification to update the continuity information on page 1. This amendment updates the status of U.S. Application Serial No. 09/839,253, filed on 4/20/2001, which has now issued as U.S. Patent No. 6,682,520. No new matter has been added.

**Rejections under 35 U.S.C. §112**

Claim 7 was rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement.

Without acceding to the propriety of the rejection, Applicant has amended claim 7 to depend directly from claim 2 instead of claim 5. Basis for the fibrinogen and fibrinogen activator being administered separately can be found, *inter alia*, on page 12, lines 15-18. Therefore, Applicant submits that this amendment obviates the rejection. Accordingly, reconsideration and withdrawal of the rejection of claim 7 under 35 U.S.C. §112, first paragraph, is respectfully requested.

**Double Patenting Rejection**

Claims 1-6 and 13-18 stand rejected under the doctrine of obviousness-type double patenting as being unpatentable over claims 1-2, 5-8, 14-16 and 19-24 of U.S. Patent No. 6,682,520. Claims 7-12 stand rejected under the doctrine of obviousness-type double patenting as being unpatentable over claims 1-2 of U.S. Patent No. 6,682,520 in view of Edwardson et al. (U.S. Patent No. 5,739,288).

Without acceding to the propriety of the double patenting rejection, Applicant herewith submits a Terminal Disclaimer (and a Statement Under 37 CFR 3.73(b)) to overcome the rejections. The record should reflect that the filing of the Terminal Disclaimer is not an

admission by Applicant that the claims of the present invention are obvious in view of the claims of the '520 patent, alone or in view of Edwardson et al.

Accordingly, withdrawal of the rejection of claims 1-18 is respectfully requested.

**CONCLUSION**

A Notice of Allowance is respectfully requested. The Examiner is requested to call the undersigned at the telephone number listed below if this communication does not place the case in condition for allowance.

If this response is not considered timely filed and if a request for an extension of time is otherwise absent, Applicant hereby requests any necessary extension of time. If there is a fee occasioned by this response, including an extension fee, that is not covered by an enclosed check, please charge any deficiency to Deposit Account No. 23/2825.

Respectfully submitted,

By:

  
\_\_\_\_\_  
Patrick R.H. Waller, Ph.D., Reg. No. 41,418  
Amy F. Mendel, Reg. No. 55,452  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2206  
Telephone: (617) 646-8000

Docket No.: B1136.70000US04  
Date: January 24, 2005